The camizestrant approval granted by the US Food and Drug Administration on 4 September 2026 sets an oncology precedent. It is the first US clearance of a cancer therapy triggered by a resistance mutation found in blood. The agency made that claim itself. The trigger arrives before any scan shows the disease growing.
AstraZeneca will sell the drug as Etcamah. The approved US indication covers adults with hormone receptor positive, HER2 negative, locally advanced or metastatic breast cancer. Eligibility opens on detection of an ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy. The dose is 75 mg once daily, taken alongside abemaciclib, palbociclib or ribociclib.
What the FDA actually cleared
The camizestrant approval is an accelerated approval, not a full one. Continued approval may depend on verification of clinical benefit in a confirmatory trial. That condition is standard for the pathway, and LSDN has set out how accelerated approval works. The Guardant360 CDx assay is the approved companion diagnostic.
Angelo de Claro, Director of the Oncology Center of Excellence, framed the significance narrowly. He called it the first FDA approval of a cancer therapy guided by ctDNA detection. Acting FDA Commissioner Kyle Diamantas described the decision as a win for patients facing metastatic disease. Neither quote engaged with the April vote. The announcement notes the meeting and flags the outstanding evidence question.
The camizestrant approval followed a negative advisory vote
The FDA’s Oncologic Drugs Advisory Committee met on 30 April 2026. It voted six to three against a favourable benefit risk assessment for the combination. AstraZeneca confirmed the outcome in a statement issued the same day. Susan Galbraith, Executive Vice President of Oncology Haematology R&D, said the company was disappointed.
Committee members did not dispute the progression free survival result. Stanley Lipkowitz of the National Cancer Institute put the objection plainly. “There is a PFS benefit. There was no OS benefit,” he said. Members worried that approval would endorse a treatment paradigm without established clinical benefit.
The agency then extended its decision date on 27 May 2026. AstraZeneca said it had submitted ctDNA clearance data linked to longer term efficacy outcomes. That submission also addressed the questions the committee had raised in April. The FDA cleared the application a little over three months later.
What the label carries that the announcement did not
AstraZeneca’s US approval release said no new safety concerns were identified. The label tells a fuller story. The FDA announcement records a boxed warning for irregular heart rhythm. That risk applies when the drug is taken with certain other medicines. Warnings also cover bradycardia and embryo foetal toxicity.
The trial safety data cut both ways. Grade 3 or higher adverse events reached 60 per cent on camizestrant. The continued aromatase inhibitor arm recorded 46 per cent. Neutropenia ran at 45 per cent against 34 per cent, and leukopenia at 10 per cent against 3 per cent.
Other measures favoured the switch. Discontinuations stayed low in both arms, at 1 per cent and 2 per cent. AstraZeneca reported time to deterioration in global health status of 23.0 months against 6.4 months. It gave a hazard ratio of 0.53 for that exploratory endpoint. The published trial data record 21.0 months against 6.4 months, with a hazard ratio of 0.54.
Europe and the UK cleared it months earlier
The camizestrant approval in the US came after clearances elsewhere. Etcamah was already cleared in more than 30 countries, including Japan and Canada. The European Commission granted approval on 23 July 2026. That decision did not use an accelerated route. The AstraZeneca announcement records no confirmatory trial condition.
The EU indication differs from the US wording in one respect. Brussels requires the ESR1 mutation to be detected without disease progression during first line endocrine therapy. The US wording does not carry that clause. The SERENA-6 protocol itself required no progression at randomisation. Prescribers on either side of the Atlantic are therefore reading slightly different labels.
The MHRA moved before the FDA as well. The Institute of Cancer Research announced the UK approval on 7 August 2026. LSDN could not establish the exact authorisation date from the agency’s own published record as at 8 September 2026.
The Institute of Cancer Research puts UK breast cancer diagnoses at about 55,000 a year. Professor Nick Turner welcomed the UK decision at the time. He is Professor of Molecular Oncology at The Institute of Cancer Research, London. He is also Director of Clinical Research at The Royal Marsden NHS Foundation Trust. “This approach shifts cancer care from reacting to disease progression to anticipating it,” he said.
What SERENA-6 showed, and what it did not
SERENA-6 randomised 315 patients, and the study is registered as NCT04964934. Median progression free survival was 16.0 months against 9.2 months on continued aromatase inhibitor. The hazard ratio was 0.44, with a 95 per cent confidence interval of 0.31 to 0.60. AstraZeneca reported a p value below 0.00001.
Time to second progression favoured the switch as well. Medians were 25.7 months against 19.1 months, with a hazard ratio of 0.63. Total ctDNA clearance reached 51.0 per cent against 1.9 per cent on the control arm.
Overall survival remained immature at the final reported analysis. The hazard ratio was 0.87, with a confidence interval of 0.57 to 1.30. That interval crosses one. The committee objection in April rested on exactly this point.
The extended analysis was published online in The Lancet Oncology in July 2026. It appears in the August issue. Nicholas Turner is its first author and Francois-Clement Bidard its last. The trial ran as a two step, double blind, placebo controlled study.
The monitoring burden behind 315 patients
The randomised population is the visible part of a much larger exercise. Eleanor Taranto and Angela DeMichele set out the numbers in npj Breast Cancer in January 2026. SERENA-6 screened 3,256 patients to find 548 with a detectable ESR1 mutation. Of those, 315 were randomised. Fewer than one in ten screened patients reached the treatment phase.
The two authors were not persuaded that the strategy is ready for routine use. They concluded that ctDNA guided molecular progression “isn’t yet ready for primetime”. Their comment predates both the advisory vote and the approval. Their caveat sits alongside the camizestrant approval rather than against it. The FDA cleared the drug, and the clinical utility question stays open.
The UK access question this approval opens
England already tests for ESR1 mutations in circulating tumour DNA. The National Genomic Test Directory carries the test under code M3.13. NHS Genomic Medicine Service guidance triggers that test at disease progression. SERENA-6 tested every two to three months in patients who had not progressed.
The commissioning logic follows NICE. Technology appraisal TA1036 recommends elacestrant after progression on endocrine treatment plus a CDK4/6 inhibitor. That is a post progression pathway, and the testing sits inside it. Serial monitoring before progression is a different service with a different cost base. It requires repeat sampling in patients who feel well and look stable on treatment. Laboratory capacity, turnaround times and clinic follow-up would all need to absorb that.
LSDN found no published NICE appraisal covering camizestrant in the advanced ESR1 setting as at 8 September 2026. An appraisal is in development for an early breast cancer indication instead. Nothing here represents a NICE position, and the observation is LSDN’s own.
What the camizestrant approval leaves unresolved
The commercial case for the camizestrant approval rests on where the drug goes next. Leerink Partners has put revenue from the SERENA-6 setting at roughly 750 million US dollars. The firm sees a larger, non risk adjusted opportunity of about 2.8 billion dollars if SERENA-4 reads out well. It puts the chance of that trial succeeding at 20 per cent. AstraZeneca has tipped the asset to generate peak sales above 5 billion dollars. Those are projections rather than results.
SERENA-4 compares camizestrant plus palbociclib against anastrozole plus palbociclib in first line disease. LSDN could not confirm from the FDA announcement which trial carries the confirmatory obligation. Elacestrant already holds the post progression position in both the US and England. Two further oral selective oestrogen receptor degraders, imlunestrant and vepdegestrant, are also in development. None of them is licensed for a switch made before imaging shows progression.
Investors marked the stock down after the advisory vote in the spring. LSDN did not independently verify a share price move on the approval itself.
The precedent is what trade readers should watch. A blood test now moves a patient onto a new therapy in the United States, before imaging changes. Whether payers, genomics services and guideline bodies follow is a separate question. LSDN tracks pending decisions in its FDA drug approval decisions coverage.
